Advances in Novel Biomarkers for Kidney Cancer
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Genitourinary Oncology".
Deadline for manuscript submissions: 15 June 2026 | Viewed by 498
Special Issue Editor
Special Issue Information
Dear Colleagues,
Approximately 400,000 new cases of kidney cancer are diagnosed annually across the globe. While a majority of cases are detected incidentally and at low stages, those with metastatic disease may only have a 15% 5-year survival. In addition, those with local disease on presentation may experience recurrence after initial treatment. Thus, it is important to properly risk stratify patients for appropriate treatment decisions.
Currently, there are no blood- or tissue-based biomarkers for kidney cancer that are widely adopted for clinical practice. This need has led to considerable interest and research in the field, with exciting advances such as the creation of immunologic or multigene signatures, circulating tumor DNA, and evaluation urine- and blood-based biomarkers.
This Special Issue of Current Oncology will focus on emerging biomarkers in kidney cancer, including performance in differentiating benign or malignant renal masses, localized, high-risk localized, or metastatic disease. All subtypes of kidney cancer will be addressed.
Dr. Brittney Hanerhoff Cotta
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- kidney cancer
- renal cell carcinoma
- biomarkers
- genomics
- risk stratification
- prognosis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
